Casara Hong1, Michael Legal2, Harkaryn Bagri3, Louise Lau4, Karen Dahri5. 1. , BSc, PharmD, ACPR, is with St Paul's Hospital, Providence Health Care, Vancouver, British Columbia. 2. , BSc(Pharm), PharmD, ACPR, FCSHP, is with St Paul's Hospital, Providence Health Care, and the Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia. 3. , BSc, BSc(Pharm), ACPR, is with Surrey Memorial Hospital, Fraser Health Authority, Surrey, British Columbia. 4. , BSc, BSc(Pharm), ACPR, is with Vancouver General Hospital, Vancouver Coastal Health, Vancouver, British Columbia. 5. , BSc, BSc(Pharm), PharmD, ACPR, FCSHP, is with Vancouver General Hospital, Vancouver Coastal Health, and the Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia.
Abstract
Background: Clinical decision support systems (CDSS) are used by pharmacists to assist in managing drug-drug interactions (DDIs). However, previous research suggests that such systems may perform suboptimally in providing clinically relevant information in practice. Objectives: The primary objective of this study was to develop a novel DDI management tool to reflect the clinical thought process that a pharmacist uses when assessing a DDI. The secondary objective was to investigate practitioners' perceptions of this tool. Methods: This study was conducted in 3 phases: development of the DDI management tool, implementation of the tool in clinical practice, and collection of practitioners' opinions of the tool through an online qualitative survey (although because of circumstances related to the COVID-19 pandemic, the study population for the survey phase included only pharmacy residents). A comprehensive literature search and analysis by an expert panel provided underlying context for the DDI management tool. The tool was validated through simulation against a known list of DDIs before implementation into practice by hospital pharmacists and pharmacy residents. Participating pharmacy residents were invited to provide feedback on the tool. Survey results were analyzed using descriptive statistics. Results: The novel tool that was developed in this study (called TLC-Act) consisted of components important to a pharmacist when assessing a DDI, including the duration of concomitant use of the interacting medications and patient-specific risk factors. Study participants implemented the tool in clinical practice for a total of 6 weeks. Of the 28 pharmacy residents surveyed, 15 (54%) submitted a response, of whom 11 (73%) found the TLC-Act tool to be slightly more useful for assessing a DDI than usual care with the CDSS alone. Conclusions: The TLC-Act tool maps out a pharmacist's clinical thought process when assessing a DDI in practice. This novel tool may be more useful than a CDSS alone for managing DDIs, as it takes into account other important factors pertinent to the assessment of a DDI. 2022 Canadian Society of Hospital Pharmacists. All content in the Canadian Journal of Hospital Pharmacy is copyrighted by the Canadian Society of Hospital Pharmacy. In submitting their manuscripts, the authors transfer, assign, and otherwise convey all copyright ownership to CSHP.
Background: Clinical decision support systems (CDSS) are used by pharmacists to assist in managing drug-drug interactions (DDIs). However, previous research suggests that such systems may perform suboptimally in providing clinically relevant information in practice. Objectives: The primary objective of this study was to develop a novel DDI management tool to reflect the clinical thought process that a pharmacist uses when assessing a DDI. The secondary objective was to investigate practitioners' perceptions of this tool. Methods: This study was conducted in 3 phases: development of the DDI management tool, implementation of the tool in clinical practice, and collection of practitioners' opinions of the tool through an online qualitative survey (although because of circumstances related to the COVID-19 pandemic, the study population for the survey phase included only pharmacy residents). A comprehensive literature search and analysis by an expert panel provided underlying context for the DDI management tool. The tool was validated through simulation against a known list of DDIs before implementation into practice by hospital pharmacists and pharmacy residents. Participating pharmacy residents were invited to provide feedback on the tool. Survey results were analyzed using descriptive statistics. Results: The novel tool that was developed in this study (called TLC-Act) consisted of components important to a pharmacist when assessing a DDI, including the duration of concomitant use of the interacting medications and patient-specific risk factors. Study participants implemented the tool in clinical practice for a total of 6 weeks. Of the 28 pharmacy residents surveyed, 15 (54%) submitted a response, of whom 11 (73%) found the TLC-Act tool to be slightly more useful for assessing a DDI than usual care with the CDSS alone. Conclusions: The TLC-Act tool maps out a pharmacist's clinical thought process when assessing a DDI in practice. This novel tool may be more useful than a CDSS alone for managing DDIs, as it takes into account other important factors pertinent to the assessment of a DDI. 2022 Canadian Society of Hospital Pharmacists. All content in the Canadian Journal of Hospital Pharmacy is copyrighted by the Canadian Society of Hospital Pharmacy. In submitting their manuscripts, the authors transfer, assign, and otherwise convey all copyright ownership to CSHP.
Authors: Meredith Young; Aliki Thomas; David Gordon; Larry Gruppen; Stuart Lubarsky; Joseph Rencic; Tiffany Ballard; Eric Holmboe; Ana Da Silva; Temple Ratcliffe; Lambert Schuwirth; Steven J Durning Journal: Med Teach Date: 2019-07-17 Impact factor: 3.650
Authors: María Espinosa-Bosch; Bernardo Santos-Ramos; María Victoria Gil-Navarro; María Dolores Santos-Rubio; Roberto Marín-Gil; Paloma Villacorta-Linaza Journal: Int J Clin Pharm Date: 2012-09-11
Authors: G Ross Baker; Peter G Norton; Virginia Flintoft; Régis Blais; Adalsteinn Brown; Jafna Cox; Ed Etchells; William A Ghali; Philip Hébert; Sumit R Majumdar; Maeve O'Beirne; Luz Palacios-Derflingher; Robert J Reid; Sam Sheps; Robyn Tamblyn Journal: CMAJ Date: 2004-05-25 Impact factor: 8.262
Authors: Hugh Tilson; Lisa E Hines; Gerald McEvoy; David M Weinstein; Philip D Hansten; Karl Matuszewski; Marianne le Comte; Stefanie Higby-Baker; Joseph T Hanlon; Lynn Pezzullo; Kathleen Vieson; Amy L Helwig; Shiew-Mei Huang; Anthony Perre; David W Bates; John Poikonen; Michael A Wittie; Amy J Grizzle; Mary Brown; Daniel C Malone Journal: Am J Health Syst Pharm Date: 2016-04-15 Impact factor: 2.637